Marshall Wace
MGX icon

Marshall Wace’s Metagenomi Therapeutics MGX Stock Holding History

Marshall Wace’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,521
Closed -$36.9K – 3834
2026
Q1 		$36.9K Sell
27,521
-51,615
-65% -$80.2K ﹤0.01% 3005
2025
Q4 		$128K Sell
79,136
-12,169
-13% -$26.3K ﹤0.01% 2676
2025
Q3 		$216K Sell
91,305
-58,989
-39% -$120K ﹤0.01% 2549
2025
Q2 		$222K Buy
+150,294
New +$235K ﹤0.01% 2428
2025
Q1 		– Sell
-47,922
Closed -$173K – 3166
2024
Q4 		$173K Sell
47,922
-120,717
-72% -$291K ﹤0.01% 2378
2024
Q3 		$366K Hold
168,639
– – ﹤0.01% 2054
2024
Q2 		$688K Sell
168,639
-14,388
-8% -$98.9K ﹤0.01% 1836
2024
Q1 		$1.93M Buy
+183,027
New +$2.1M ﹤0.01% 1380

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace's MGX Position: Q2 2026 in Review

Marshall Wace sold out of Metagenomi Therapeutics (MGX) in Q2 2026, closing a stake of 27,521 shares — an estimated $36.9K sold.

Marshall Wace first reported a position in MGX in Q1 2024 and held it in 8 quarters. The position peaked at $1.93M in Q1 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Marshall Wace reported no remaining Metagenomi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 27,521 Metagenomi Therapeutics shares in Q2 2026, an estimated $36.9K.
  • Marshall Wace first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 8 quarters.
  • Marshall Wace's Metagenomi Therapeutics position peaked at $1.93M in Q1 2024.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.